MRD
ASH 2021: a deep dive into ALL immunotherapy
Various forms of immunotherapy represent a novel treatment option, especially for patients who progress from conventional chemotherapy hematopoietic stem-cell transplantation…
Date: 25th March 2022
ASH 2021: highlights in CLL clinical trials
Treatments such as ibrutinib and venetoclax, which target the Bruton tyrosine kinase (BTK) pathway and the B-cell lymphoma 2 (BCL-2)…
Date: 18th February 2022
IMW 2021: treatment-free intervals in multiple myeloma
Continuous therapy has been a key aspect of the standard of care approaches for the treatment of multiple myeloma for…
Date: 29th September 2021
IMW 2021: MRD in myeloma
Measurable residual disease (MRD) is emerging as an important prognostic marker in the management of multiple myeloma. Promising clinical evidence…
Date: 20th September 2021
The Myeloma Sessions: key highlights from EHA and ASCO 2021
The introduction of many novel drug classes and therapies has resulted in significant improvements in overall survival outcomes for patients…
Date: 21st July 2021
EHA 2021: fixed-duration therapies and sequencing in CLL
Over the last years, the chronic lymphocytic leukemia (CLL) field has seen significant growth in new drugs and new treatment…
Date: 8th July 2021
The AML Sessions: Highlights from ASCO/EHA 2021
Acute myeloid leukemia (AML) is a clonal hematologic malignancy defined by genetic heterogeneity due to recurrent gene mutations. Precision medicine…
Date: 7th July 2021
EHA 2021: MRD in myeloma
Over the past ten years, the approval of several new and effective therapies for multiple myeloma has significantly improved overall…
Date: 25th June 2021
Latest updates on CAR-T therapy for CLL
Chronic lymphocytic leukemia (CLL) is slow to develop and can be hard to treat as patients relapse or become refractory…
Date: 16th June 2021
The Lymphoma Sessions: ASH 2020 highlights
The treatment of aggressive lymphomas such as diffuse large B-cell has seen dramatic changes, and with the advent of bispecific…
Date: 23rd April 2021
The Myeloma Sessions: Post-ASH 2020 UK Discussion
The development of immunomodulatory agents and proteasome inhibitors alongside stem cell transplantation and chemotherapy has significantly improved the treatment options…
Date: 19th April 2021
Post-ASH Amyloidosis Session from VJHemOnc
The most common form of amyloidosis, light-chain (AL) amyloidosis, results from abnormalities in plasma cells causing them to produce abnormal…
Date: 13th April 2021
